NASDAQ:LIVN

LivaNova - LIVN Stock Forecast, Price & News

$50.77

+2.40 (+4.96%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $48.46
▼
$52.90
50-Day Range: $48.37
▼
$66.50
52-Week Range: $47.09
▼
$93.89

Volume: 629,875 shs
Average Volume: 367,323 shs
Market Capitalization: $2.71 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $90.20

LivaNova MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 77.7% Upside
$90.20 Price Target
Short Interest: Bearish
4.27% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.32
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 32.46%
From $1.91 to $2.53 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

413th out of 1,093 stocks

Electromedical Equipment Industry

4th out of 23 stocks

3.5

Analyst's Opinion

Consensus Rating
LivaNova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $90.20, LivaNova has a forecasted upside of 77.7% from its current price of $50.77.
Amount of Analyst Coverage
LivaNova has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.27% of the outstanding shares of LivaNova have been sold short.
Short Interest Ratio / Days to Cover
LivaNova has a short interest ratio ("days to cover") of 5.7.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
LivaNova does not currently pay a dividend.
Dividend Growth
LivaNova does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LIVN.

2.4

News and Social Media Coverage

News Sentiment
LivaNova has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for LivaNova this week, compared to 2 articles on an average week.
Search Interest
2 people have searched for LIVN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, LivaNova insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.38% of the stock of LivaNova is held by insiders.
Percentage Held by Institutions
98.89% of the stock of LivaNova is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for LivaNova are expected to grow by 32.46% in the coming year, from $1.91 to $2.53 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of LivaNova is -90.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of LivaNova is -90.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
LivaNova has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About LivaNova (NASDAQ:LIVN) Stock

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LIVN Stock News Headlines

October 1, 2022 | americanbankingnews.com

LivaNova (NASDAQ:LIVN) Hits New 1-Year Low at $47.19

September 30, 2022 | nasdaq.com

21%of this LivaNova PLC (NASDAQ:LIVN) insider's holdings were sold in the last year - Nasdaq

September 30, 2022 | benzinga.com

FDA Says Livanova Recalls Lifesparc System For Risk Of Unintentional Extended Pump Stop During Controller - Benzinga

September 30, 2022 | seekingalpha.com

FDA labels recall of blood bypass pump systems by LivaNova as most serious - Seeking Alpha

September 30, 2022 | nasdaq.com

LivaNova Enters Oversold Territory (LIVN)

September 27, 2022 | finance.yahoo.com

Neuromodulation Devices Global Market - Forecast To 2029 - Yahoo Finance

September 26, 2022 | benzinga.com

Worldwide Heart Lung Machine Industry to 2031 - Featuring Hemovent, LivaNova, Medtronic and Nipro Among O - Benzinga

September 16, 2022 | finance.yahoo.com

Outlook on the Endoscopic Vessel Harvesting System Global Market to 2027 - Growing Healthcare Market Presents Opportunities - Yahoo Finance

September 14, 2022 | bizjournals.com

2022 Fire Awards, Exits of the Year: ALung Technologies - The Business Journals

September 12, 2022 | finance.yahoo.com

Internal Neurostimulation Devices Market is Thriving at CAGR Of +17.4% by 2029, Size, Share, Emerging Trends, Historic Analysis, Competitive Landscape and Industry Growth Factors - Yahoo Finance

September 8, 2022 | bizjournals.com

Carlson Center's small neighbors sign new tenants, including Roers Cos. - The Business Journals

August 26, 2022 | nasdaq.com

Slowing Rates Of Return At LivaNova (NASDAQ:LIVN) Leave Little Room For Excitement - Nasdaq

August 24, 2022 | reuters.com

LIVN.O - LivaNova PLC | Stock Price & Latest News | Reuters

August 18, 2022 | nasdaq.com

Sum Up The Parts: IVOO Could Be Worth $200 - Nasdaq

August 12, 2022 | msn.com

LivaNova's Return on Invested Capital Overview

August 10, 2022 | benzinga.com

LivaNova's Return on Invested Capital Overview - Benzinga

August 4, 2022 | seekingalpha.com

LivaNova: Value Gap To The Downside, Rate Neutral (NASDAQ:LIVN) - Seeking Alpha

August 3, 2022 | finance.yahoo.com

LivaNova (LIVN) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance

August 3, 2022 | investing.com

LivaNova plc Tops Q2 EPS by 1c By Investing.com - Investing.com

August 3, 2022 | benzinga.com

Recap: LivaNova Q2 Earnings - Benzinga

August 3, 2022 | in.investing.com

LivaNova plc Tops Q2 EPS by 1c By Investing.com - Investing.com India

August 3, 2022 | seekingalpha.com

LivaNova Non-GAAP EPS beats by $0.01, revenue beats by $4.65M lowers FY earning guidance - Seeking Alpha

August 3, 2022 | businesswire.com

LivaNova Reports Second-Quarter 2022 Results - Business Wire

July 31, 2022 | finance.yahoo.com

Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)

July 27, 2022 | businesswire.com

Global Pacemakers Pipeline Insight and Competitive Landscape 2022: Featuring Key Players Medtronic, Boston Scientific Corporation, Biotronik Se & Co, LivaNova & Abbott Laboratories - ResearchAndMarkets.com - Business Wire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LIVN Company Calendar

Last Earnings: 8/03/2022
Today: 10/01/2022
Next Earnings (Confirmed): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LIVN
CUSIP: N/A
CIK: 1639691
Web: www.livanova.com
Phone: 442033250660
Fax: 281-218-9332
Employees: 3,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $90.20
High Stock Price Forecast: $99.00
Low Stock Price Forecast: $73.00
Forecasted Upside/Downside: +77.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 26.58
P/E Growth: N/A
Net Income: $-135,820,000.00
Net Margins: -2.74%
Pretax Margin: -1.90%
Return on Equity: 9.35%
Return on Assets: 5.29%

Debt

Debt-to-Equity Ratio: 0.36
Current Ratio: 2.93
Quick Ratio: 2.47

Sales & Book Value

Annual Sales: $1.04 billion
Price / Sales: 2.62
Cash Flow: $3.77 per share
Price / Cash Flow: 13.45
Book Value: $24.32 per share
Price / Book: 2.09

Miscellaneous

Outstanding Shares: 53,440,000
Free Float: 53,238,000
Market Cap: $2.71 billion
Optionable: Optionable
Beta: 0.91

Key Executives

Mr. Damien McDonald (Age 57)
CEO & Director
Comp: $3.48M

Mr. Alex Shvartsburg (Age 51)
Chief Financial Officer
Comp: $888.04k

Ms. Keyna Pidcock Skeffington (Age 59)
Sr. VP, Gen. Counsel & Corp. Sec.
Comp: $1.19M

Ms. Trui Hebbelinck (Age 50)
Chief HR Officer
Comp: $945.32k

Mr. Marco Dolci (Age 60)
Pres of Cardiopulmonary Bus. Unit
Comp: $1.29M

Lindsey Little
Sr. Director of Investor Relations

Deanna Wilke
VP of Corp. Communications

Mr. Matthew Joseph Dodds III
Sr. VP of Corp. Devel.

Dr. Bryan D. Olin Ph.D. (Age 55)
Sr. VP & Head of Product Devel. - Neuromodulation

Mr. Paul R. Buckman (Age 66)
Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LIVN Stock - Frequently Asked Questions

Should I buy or sell LivaNova stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LIVN shares.
View LIVN analyst ratings or view top-rated stocks.
What is LivaNova's stock price forecast for 2022?: 5 analysts have issued 1 year target prices for LivaNova's stock. Their LIVN share price forecasts range from $73.00 to $99.00. On average, they predict the company's stock price to reach $90.20 in the next twelve months. This suggests a possible upside of 77.7% from the stock's current price.
View analysts price targets for LIVN or view top-rated stocks among Wall Street analysts.
How have LIVN shares performed in 2022?: LivaNova's stock was trading at $87.43 at the beginning of 2022. Since then, LIVN stock has decreased by 41.9% and is now trading at $50.77.
View the best growth stocks for 2022 here.
When is LivaNova's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our LIVN earnings forecast.
How can I listen to LivaNova's earnings call?: LivaNova will be holding an earnings conference call on Wednesday, November 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were LivaNova's earnings last quarter?: LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings data on Wednesday, August, 3rd. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.02. The firm had revenue of $254.20 million for the quarter, compared to analysts' expectations of $249.55 million. LivaNova had a negative net margin of 2.74% and a positive trailing twelve-month return on equity of 9.35%. LivaNova's quarterly revenue was down 3.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.52 EPS.

What guidance has LivaNova issued on next quarter's earnings?: LivaNova updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of $2.25-$2.45 for the period, compared to the consensus earnings per share estimate of $2.58. The company issued revenue guidance of $1.08 billion-$1.10 billion, compared to the consensus revenue estimate of $1.03 billion.
What is Damien McDonald's approval rating as LivaNova's CEO?: 47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.
What other stocks do shareholders of LivaNova own?: Based on aggregate information from My MarketBeat watchlists, some companies that other LivaNova investors own include BioTelemetry (BEAT), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Genocea Biosciences (GNCA), AbbVie (ABBV), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), Chipotle Mexican Grill (CMG) and CRISPR Therapeutics (CRSP).
What is LivaNova's stock symbol?: LivaNova trades on the NASDAQ under the ticker symbol "LIVN."
How do I buy shares of LivaNova?: Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is LivaNova's stock price today?: One share of LIVN stock can currently be purchased for approximately $50.77.
How much money does LivaNova make?: LivaNova (NASDAQ:LIVN) has a market capitalization of $2.71 billion and generates $1.04 billion in revenue each year. The company earns $-135,820,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.
How many employees does LivaNova have?: The company employs 3,000 workers across the globe.
How can I contact LivaNova?: LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The official website for the company is www.livanova.com. The company can be reached via phone at 442033250660, via email at investor.relations@livanova.com, or via fax at 281-218-9332.

This page (NASDAQ:LIVN) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

LivaNova - LIVN Stock Forecast, Price & News

LivaNova MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month